Try our beta test site

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2017 by Catalyst Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
Catalyst Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT02562066
First received: September 24, 2015
Last updated: January 31, 2017
Last verified: January 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2017
  Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)